Positive data on new antidepressant from Lundbeck
![Foto: PR lundbeck](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article3003167.ece/ALTERNATES/schema-16_9/lundbeck7.jpg)
Lundbeck’s candidate drug, the antidepressant Brintellix, performs better than a possible rival drug, Valdoxan (agomelatin), in patients with major depression and inadequate response to SSRI or SNRI therapy, results from a recently concluded phase III trial with the two drugs indicate, according to a statement released on Monday.
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.